Login to Your Account

Clinic Roundup

Wednesday, September 5, 2012
GenSpera Inc., of San Antonio, said UK regulators cleared the firm for a Phase II trial of G-202 in prostate cancer patients who have failed prior hormonal therapy. The study is expected to enroll up to 40 patients with chemotherapy-naïve, metastatic castrate-resistant disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription